Information Provided By:
Fly News Breaks for January 8, 2020
Jan 8, 2020 | 07:13 EDT
H.C. Wainwright analyst Edward White lowered his price target for Clovis Oncology to $27 from $36 after the company announced preliminary Q4 Rubraca revenue at the lower end of the prior guidance. The analyst, however, reiterates a Buy rating on the shares.
News For CLVS From the Last 2 Days
There are no results for your query CLVS